{
    "body": "Which drugs are included in TAS-102?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26557901", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26084259", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25776904", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25256052", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25230742", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25750295"
    ], 
    "ideal_answer": [
        "TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5."
    ], 
    "exact_answer": [
        [
            "trifluridine"
        ], 
        [
            "tipiracil"
        ]
    ], 
    "type": "list", 
    "id": "56c1f000ef6e394741000037", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 188, 
            "text": "PURPOSE: Trifluridine (TFT) is an antitumor component of a novel nucleoside antitumor agent, TAS-102, which consists of TFT and tipiracil hydrochloride (thymidine phosphorylase inhibitor).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26084259", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 743, 
            "offsetInEndSection": 960, 
            "text": "TAS-102, a combination of trifluorothymidine and the thymidine phosphorylase inhibitor TPI in a 1:0.5 ratio, is a novel oral formulation, which is active in 5FU-resistant models, both in vitro and in xenograft models.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26557901", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 133, 
            "text": "TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25750295", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 148, 
            "text": "PURPOSE: TAS-102 is an orally administered anticancer agent composed of \u03b1,\u03b1,\u03b1-trifluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25776904", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 721, 
            "offsetInEndSection": 1044, 
            "text": "Novel DNA synthesis inhibitors for the treatment of gastrointestinal malignancies include a combination of the antimetabolite TAS-102, which consists of trifluorothymidine with a thymidine phosphorylase inhibitor, and a novel micellar formulation of cisplatin NC-6004 that uses a nanotechnology-based drug delivery system. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25256052", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 130, 
            "text": "Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230742", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 116, 
            "text": "TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine (FTD) and tipiracil hydrochloride (TPI).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230742", 
            "endSection": "abstract"
        }
    ]
}